{'fraction_non_alphanumeric': 0.03949044585987261, 'fraction_numerical': 0.008917197452229299, 'mean_word_length': 6.86, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of long‐term L‐threo‐3,4‐dihydroxyphenylserine administration on α‐2‐adrenergic receptors in platelet membranes in neurologic disorders

ABSTRACT The effects of L‐threo‐3,4‐dihydroxyphenylserine (L‐threo‐DOPS). an unnatural norepinephrine precursor, on α2,‐adrenergic receptors in platelet membranes were investigated in a patient with familial amyloidotic polyneuropathy, two patients with multiple system atrophy, and two patients with Parkinson's disease. Each patient was treated for at least six months. While L‐threo‐DOPS alone, or in combination with decarboxylase inhibitor benserazide hydrochloride, produced sustained increase in plasma norepinephrine and clinical improvement, it did not induce a change in the number of α2‐adrenergic receptors in platelet membranes.